Health TrialsbyHealthPanel

Etomidate Versus Propofol in CABG Surgery

ConditionCoronary Artery Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-90
SponsorHartford Hospital

About this trial

The objective of this single-blinded randomized controlled interventional clinical trial is to learn about the efficacy and long-term safety of etomidate compared to propofol as an anesthesia induction agent in patients undergoing coronary artery bypass graft (CABG) surgery. The primary aim of this study is to determine whether patients receiving etomidate or propofol exhibit similar requirements for vasopressor or ionotropic agents during both the intraoperative and postoperative periods.

To achieve this goal, participants who are scheduled for CABG surgery will be randomly assigned to receive either etomidate or propofol as the principal hypnotic agent. The researchers will then compare the effects of these two anesthesia induction agents on various factors, including the need for hemodynamic support, hemodynamic stability, duration of mechanical ventilation, length of stay in the intensive care unit (ICU), and overall hospital length of stay. Additionally, they will assess whether there are disparities in mortality rates and readmission rates within a 6-month timeframe after the surgery.

By comparing the outcomes between the two groups, the study aims to provide valuable insights into the potential differences in vasopressor or ionotropic agent requirements between etomidate and propofol. This information can help inform clinical decision-making and potentially optimize anesthesia management strategies for patients undergoing CABG surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients scheduled for elective open coronary arteries bypass graft CABG surgery

Patients with American Society of Anesthesiology (ASA) physical status score I- IV

Patients with the ability to speak and read both English and Spanish

Disqualifiers

Emergency CABG surgery, STAT cases, and add-on cases.

Refusal or lack of providing the study consent

Patients with a known current adrenocortical insufficiency

A patient who is presenting with any kind of shock, (e.g. septic, hypovolemic, cardiogenic, etc.)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Etomidate

    Drug

    The type of general anesthesia induction agent for CABG surgery

  • Propofol

    Drug

    The type of general anesthesia induction agent for CABG surgery

Treatment groups

300 Participants
are divided into 2 treatment groups
Group A: EtomidateExperimental treatment 1 intervention
Group B: PropofolActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Vasopressors dose expressed by Noradrenaline Equivalent dose [μg/kg/min]

Vasopressor requirements will be expressed as Noradrenaline Equivalent dose using the formula of (NEq \[μg/kg/min\] = norepinephrine + epinephrine + phenylephrine/10 + dopamine/100 + vasopressin\*2.5), this will be measured during three periods of time: Intraoperatively during the first 30 minutes post induction (as a reflection of the impact of induction on hemodynamics), intraoperatively during the last 30 minutes of the post bypass period, and for the first 24 hours post procedure.

Time frame
30 minutes after induction, last 30 minutes of post bypass period, and first 24 hours post procedure.

Secondary outcomes

1

The number of incidences of shock

The incidence of both vasogenic and cardiogenic shocks will be determined intraoperatively and postoperatively using the Mean Arterial Pressure (MAP), Central Venous Pressure (CVP), Cardiac Output (CO), and Systemic Vascular Resistance (SVR). Vasogenic shock (defined as a MAP \< 60 mmHg with normal CO (\>2.0 L/min) and low SVR (\< 900 dynes/sec). Cardiogenic shock (defined as hypotension with MAP \< 60 mmHg, low CO (\<2.0 L/min), and normal SVR range (900-1400 dynes/sec).

Time frame
First 24 hours post anesthesia
2

ICU length of stay

ICU length of stay will be calculated in hours using the ICU data from EPIC.

Time frame
3 days
3

Hospital length of stay

Hospital length of stay will be calculated in hours from the date and time of admission and discharge, from EPIC.

Time frame
7 days
4

Hospital Readmissions

In the 6th month after surgery, a retrospective safety checkup will be done, using EPIC chart review, to assess the number of readmissions.

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Hartford Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now